Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBRA phase 3 trial of rilzabrutinib in sickle cell disease
MOH_2025-04-23_013986Phase 3Not yet recruiting
- Sponsor
- Sanofi
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rilzabrutinib in sickle cell disease (SCD) (2 arms), sponsored by Sanofi. Primary endpoint: Primary endpoint not specified in registry. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
rilzabrutinib
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on MOH_2025-04-23_013986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-04-23_013986.